Clinical translation, driven through industrial partnerships and entrepreneurship, is critical to the Kennedy Institute's goal to bring new therapies from discovery research to patients.
We have over 15 major partnerships with large and small pharma companies, including Johnson & Johnson (J&J). We provide innovators with a platform to accelerate and de-risk the development of new therapies.
Translational research at the Kennedy Institute is supported by our close collaborations with nearby clinical sites, including the Oxford Experimental Medicine Clinical Research Facility located on the Churchill Hospital site just a ten-minute walk away.
Our partners benefit from access to our cutting-edge in-house technologies. We provide standalone use for specific projects, or customised workflows including multiple technologies, e.g. digital pathology and microbiome analysis, and clinical facilities.
In the software and AI space, we lead the data analysis for several large-scale collaborative projects including the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative LEGACY Network.
We supervise DPhil students sponsored by diverse pharma partners, who therefore gain access to our technologies and collaborations. We support our PIs, students, and postdoctoral researchers to engage in entrepreneurship and technology spin-out.
Get in touch
We welcome new short- and long-term industrial collaborations, and PhD sponsors, and encourage potential partners to reach out and discuss how we could work together.
Professor Mark Coles, Industrial Strategy and Entrepreneurship Lead